Abstract Number: 1758 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Infection in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of 126 Wegent Trial Patients
Background/Purpose: Adverse events, rather than active vasculitis, are the greatest threat to patients with ANCA-associated vasculitides (AAVs) during the first year of therapy but long-term…Abstract Number: 1849 • 2017 ACR/ARHP Annual Meeting
Urinary Epidermal Growth Factor and Monocyte Chemoattractant Protein-1 As Biomarkers of Renal Involvement in ANCA-Associated Vasculitis
Background/Purpose :Epidermal growth factor (EGF) mediates distal tubular epithelial cell function and regeneration. Monocyte chemoattractant protein-1 (MCP-1) participates in recruitment of leukocytes to areas of…Abstract Number: 1759 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Background/Purpose: Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s…Abstract Number: 2736 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival in Systemic Necrotizing Vasculitides
Background/Purpose: The aim of the study was to describe the evolution of mortality over recent decades in systemic necrotizing vasculitides, including polyarteritis nodosa (PAN), granulomatosis…Abstract Number: 1762 • 2017 ACR/ARHP Annual Meeting
Association of ETS1 Polymorphism in 3’ Untranslated Region with Susceptibility to Granulomatosis with Polyangiitis and Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Background/Purpose: ETS Proto-oncogene 1, transcription factor (ETS1) is a transcription factor involved in immune responses. Genome-wide association studies on systemic lupus erythematosus (SLE) in Chinese…Abstract Number: 2754 • 2017 ACR/ARHP Annual Meeting
Comparison of Individually Tailored Vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission was obtained, rituximab (RTX) superiority to azathioprine (AZA) to maintain remission was shown.1 In that study, at month 28,…Abstract Number: 797 • 2017 ACR/ARHP Annual Meeting
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
Background/Purpose: Giant cell arteritis (GCA) is a non-necrotizing granulomatous arteritis involving large vessels, whereas antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a group of necrotizing…Abstract Number: 1763 • 2017 ACR/ARHP Annual Meeting
Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry
Background/Purpose: Diagnosing ANCA-associated vasculitides (AAVs) can be challenging. Their clinical presentations are numerous and the time to diagnosis may range from days to years.1,2 The…Abstract Number: 2935 • 2017 ACR/ARHP Annual Meeting
Nasal Microbiota in Patients with Granulomatosis with Polyangiitis Compared to Healthy Controls
Background/Purpose: Prior studies have suggested a potential link between nasal microbes, in particular Staphylococcus aureus, and granulomatosis with polyangiitis (GPA; Wegener’s) but these studies relied…Abstract Number: 16L • 2016 ACR/ARHP Annual Meeting
Comparison of Systematic Vs Individually Tailored Rituximab Regimen to Maintain ANCA-Associated–Vasculitis Remission: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Background/Purpose: Remission of ANCA-associated vasculitides (AAVs) can be induced with combined glucocorticoids and cyclophosphamide or rituximab (RTX) with comparable efficacy.1 RTX superiority to azathioprine was…Abstract Number: 1923 • 2016 ACR/ARHP Annual Meeting
Activated Partial Thromboplastin Time Reflects Disease Activity in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic vasculitides associated with ANCA specific for myeloperoxidase (MPO) or proteinase-3 (PR3), and includes…Abstract Number: 1947 • 2016 ACR/ARHP Annual Meeting
Ocular Manifestations of ANCA-Associated Vasculitis
Background/Purpose: Ocular involvement in ANCA-associated vasculitis (AAV) can cause substantial morbidity. We aimed to characterize patterns of ocular involvement in AAV and their response to…Abstract Number: 1925 • 2016 ACR/ARHP Annual Meeting
Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients
Background/Purpose: The prognosis of the ANCA associated vasculitis (AAV) has improved with the new immunosuppressive treatments but infectious complications remain frequent. Procalcitonin (PCT) is…Abstract Number: 1949 • 2016 ACR/ARHP Annual Meeting
Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides
Background/Purpose: Cutaneous involvement is frequent during ANCA-associated vasculitis (AAV) and can reveal the disease. However, no large study on presentation and clinical-pathological correlations is available.…Abstract Number: 1926 • 2016 ACR/ARHP Annual Meeting
Indications for Testing and Diagnostic Outcome in Patients with Positive ANCA at a Canadian Tertiary Care Centre
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) are a hallmark of a subset of small vasculitides collectively termed ANCA-associated vasculitis (AAV). With widespread availability of ANCA testing,…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 20
- Next Page »